Fortis Healthcare plans to accumulate stake in Agilus Diagnostics
Fortis Healthcare has introduced plans to accumulate a 31% stake in its diagnostics enterprise, Agilus Diagnostics, for Rs 17.8 billion ($211.99 million).
The transaction values Agilus at Rs 57 billion.
The corporate's present shareholders, consisting of personal fairness (PE) corporations, are promoting their shares by exercising a put possibility.
NYLIM Jacob Ballas India Fund III (NJBIF) has already notified Fortis of a 15.86% stake value Rs 9.05 billion.
Fortis expects related bulletins from the opposite buyers, together with Worldwide Finance Company (IFC) and Resurgence PE Investments, earlier than 13 August.
Fortis introduced in a inventory change doc that the three non-public fairness buyers have exit rights for his or her shares in Agilus. This features a put possibility that may be exercised till 13 August, based mostly on the truthful market worth, as set out within the shareholders' settlement of 12 June 2012.
Entry probably the most complete firm profiles in the marketplace, powered by GlobalData. Save hours of analysis. Acquire a aggressive edge.
Firm Profile – Free Pattern
Your obtain e-mail will arrive shortly
We’re satisfied of the distinctive high quality of our firm profiles. Nevertheless, we would like you to take advantage of helpful choice in your firm, so we provide a free pattern which you can obtain by submitting the shape beneath
By GlobalData
Fortis already acquired a letter from NJBIF on August 7 relating to the put possibility for 12.43 million shares, representing a 15.86% stake in Agilus, for 9.05 billion rupees.
The healthcare firm is presently evaluating the required steps to adjust to the obligations arising from the shareholders' settlement, in accordance with relevant regulation.
As of March 31, 2023, Agilus operated a community of 413 laboratories, 43 of which had been accredited by the Nationwide Accreditation Board for Testing and Calibration Laboratories.
Agilus has a robust presence in India, with one international reference laboratory in Mumbai, 5 regional reference laboratories and a protection of over 1,000 cities and cities throughout 25 states and 5 union territories.
Enterprise Customary famous that the newest deal, which values Agilus at 20 instances its anticipated FY26 enterprise worth (EV) to earnings earlier than curiosity, tax, depreciation and amortisation (EBITDA), displays the sturdy development prospects of the diagnostics sector.
Agilus reported web income of Rs 3.09 billion within the first quarter of fiscal 2025, with EBITDA of Rs 555 million and a margin of 18%.
